New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePal-GHK vs Prostamax

Pal-GHK vs Prostamax

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Pal-GHK
Anti-Aging & Longevity
Prostamax
Summary
Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
Half-Life
Extended (lipid depot in stratum corneum)
Short (minutes); sustained gene-regulatory effects
Admin Route
Topical
SubQ, Oral
Research
Typical Dose
0.005–0.1% in formulation
10 mg per day
Frequency
Once or twice daily
Daily for 10–30 days
Key Benefits
  • Stimulates collagen I and III synthesis in dermis
  • Reduces the appearance of fine lines and wrinkles
  • Improves skin elasticity and firmness
  • Inhibits collagenase (MMP-1) to preserve existing collagen
  • Enhances wound healing and skin repair
  • Well-tolerated in anti-aging serums and creams
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
Side Effects
  • Generally very well-tolerated
  • Rare skin irritation at very high concentrations
  • Possible formulation-dependent comedogenicity
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
Stacks With